There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Pacira Pharmaceuticals (PCRX – Research Report) and Repare Therapeutics (RPTX – Research Report) with bullish sentiments.
Pacira Pharmaceuticals (PCRX)
In a report released today, Oren Livnat from H.C. Wainwright reiterated a Buy rating on Pacira Pharmaceuticals, with a price target of $57.00. The company’s shares closed last Thursday at $32.39.
According to TipRanks.com, Livnat is a 1-star analyst with an average return of
Currently, the analyst consensus on Pacira Pharmaceuticals is a Strong Buy with an average price target of $47.90.
See today’s best-performing stocks on TipRanks >>
Repare Therapeutics (RPTX)
H.C. Wainwright analyst Robert Burns reiterated a Buy rating on Repare Therapeutics today and set a price target of $25.00. The company’s shares closed last Thursday at $6.77.
According to TipRanks.com, Burns is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of
Repare Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $21.75.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on PCRX:
- Pacira Reports Preliminary Unaudited Fourth Quarter and Full-Year 2023 Revenues
- Pacira reports preliminary FY23 revenue $675M, consensus $677.3M
- Pacira BioSciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference
- Pacira Appoints Frank D. Lee as Chief Executive Officer
- Pacira appoints Frank Lee as CEO
